Literature DB >> 9427607

Restoration of lymphocyte function in Janus kinase 3-deficient mice by retroviral-mediated gene transfer.

K D Bunting1, M Y Sangster, J N Ihle, B P Sorrentino.   

Abstract

Janus kinase-3 (JAK3) deficiency has recently been identified as a cause of severe combined immunodeficiency (SCID) in humans. We used a mouse model of Jak3-deficient SCID to test a gene therapy approach for treatment of this disease. Transfer of a Jak3 retroviral vector to repopulating hematopoietic stem cells resulted in increased numbers of T and B lymphocytes, reversal of hypogammaglobulinemia, restoration of T-cell activation upon stimulation with mitogens, and development of an antigen-specific immune response after immunization. Analysis for vector copy number in lymphoid and myeloid populations showed a large in vivo selective advantage for Jak3-expressing lymphoid cells. These results show that gene replacement is a feasible treatment strategy for this disease and that naturally occurring in vivo selection of corrected cells is an important advantage of this approach.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9427607     DOI: 10.1038/nm0198-058

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  14 in total

1.  Jak3 selectively regulates Bax and Bcl-2 expression to promote T-cell development.

Authors:  R Wen; D Wang; C McKay; K D Bunting; J C Marine; E F Vanin; G P Zambetti; S J Korsmeyer; J N Ihle; J L Cleveland
Journal:  Mol Cell Biol       Date:  2001-01       Impact factor: 4.272

Review 2.  Severe combined immunodeficiencies (SCID).

Authors:  A Fischer
Journal:  Clin Exp Immunol       Date:  2000-11       Impact factor: 4.330

Review 3.  Gene therapy of X-linked severe combined immunodeficiency.

Authors:  Salima Hacein-Bey-Abina; Alain Fischer; Marina Cavazzana-Calvo
Journal:  Int J Hematol       Date:  2002-11       Impact factor: 2.490

Review 4.  Survival of the fittest: in vivo selection and stem cell gene therapy.

Authors:  Tobias Neff; Brian C Beard; Hans-Peter Kiem
Journal:  Blood       Date:  2005-11-03       Impact factor: 22.113

Review 5.  Hematopoietic stem cell gene therapy:assessing the relevance of preclinical models.

Authors:  Andre Larochelle; Cynthia E Dunbar
Journal:  Semin Hematol       Date:  2013-04       Impact factor: 3.851

6.  The centrosomal protein TACC3 is essential for hematopoietic stem cell function and genetically interfaces with p53-regulated apoptosis.

Authors:  Roland P Piekorz; Angelika Hoffmeyer; Christopher D Duntsch; Catriona McKay; Hideaki Nakajima; Veronika Sexl; Linda Snyder; Jerold Rehg; James N Ihle
Journal:  EMBO J       Date:  2002-02-15       Impact factor: 11.598

7.  Marking and gene expression by a lentivirus vector in transplanted human and nonhuman primate CD34(+) cells.

Authors:  D S An; R P Wersto; B A Agricola; M E Metzger; S Lu; R G Amado; I S Chen; R E Donahue
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

Review 8.  Gene transfer into hematopoietic stem cells as treatment for primary immunodeficiency diseases.

Authors:  Fabio Candotti
Journal:  Int J Hematol       Date:  2014-02-01       Impact factor: 2.490

9.  Virus-specific immunity after gene therapy in a murine model of severe combined immunodeficiency.

Authors:  K D Bunting; K J Flynn; J M Riberdy; P C Doherty; B P Sorrentino
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-05       Impact factor: 11.205

10.  Phospholipase Cgamma2 mediates RANKL-stimulated lymph node organogenesis and osteoclastogenesis.

Authors:  Yabing Chen; Xiaohong Wang; Lie Di; Guoping Fu; Yuhong Chen; Li Bai; Jianzhong Liu; Xu Feng; Jay M McDonald; Sue Michalek; Yinghong He; Mei Yu; Yang-Xin Fu; Renren Wen; Hui Wu; Demin Wang
Journal:  J Biol Chem       Date:  2008-08-26       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.